Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2025)

Xeris Biopharma Holdings' Return on Capital Employed history spans 5 years, with the latest figure at 0.09% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 24.0% year-over-year to 0.09%, compared with a TTM value of 0.09% through Dec 2025, up 24.0%, and an annual FY2025 reading of 0.1%, up 25.0% over the prior year.
  • Return on Capital Employed for Q4 2025 was 0.09% at Xeris Biopharma Holdings, up from 0.04% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.09% in Q4 2025, with the low at 0.83% in Q4 2021.
  • Average Return on Capital Employed over 5 years is 0.25%, with a median of 0.19% recorded in 2024.
  • Year-over-year, Return on Capital Employed soared 50bps in 2022 and then rose 1bps in 2024.
  • Tracing XERS's Return on Capital Employed over 5 years: stood at 0.83% in 2021, then skyrocketed by 61bps to 0.33% in 2022, then soared by 42bps to 0.19% in 2023, then increased by 21bps to 0.15% in 2024, then surged by 161bps to 0.09% in 2025.
  • Per Business Quant, the three most recent readings for XERS's Return on Capital Employed are 0.09% (Q4 2025), 0.04% (Q3 2025), and 0.04% (Q2 2025).